Plain-English translation of NCT06181370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial investigated the safety and tolerability of , a new inhaled medication, compared to placebo. Researchers tested the medication in three groups: healthy volunteers who received a single dose, healthy volunteers who received multiple doses over a week, and people diagnosed with idiopathic pulmonary fibrosis (a progressive lung scarring disease) who received multiple doses over two weeks.
Idiopathic pulmonary fibrosis is a serious condition where lung tissue becomes scarred and stiff over time, making it harder to breathe. This trial was designed to see if this new inhaled treatment could help, and to make sure it was safe enough to test further in patients.
Participants inhaled the medication or placebo using a nebulizer (a machine that turns liquid into a fine mist) either once, over 7 days, or over 14 days, depending on their group. Throughout the study, researchers conducted blood tests, breathing tests, heart monitoring, and safety checks to ensure the medication was well-tolerated and to measure how the body absorbed and responded to it.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United Kingdom